Definition

  • Homocystinuria is a group of autosomal recessive disorders of sulfur amino acid metabolism characterized by the accumulation of homocysteine (Hcy) in blood and urine.
  • Classic Homocystinuria: Due to deficiency of Cystathionine $\beta$-Synthase (CBS).
  • Other Forms: Defects in homocysteine remethylation (e.g., MTHFR deficiency, Cobalamin defects).

Etiology and Pathophysiology

1. Classic Homocystinuria (CBS Deficiency)

  • Enzyme: Cystathionine $\beta$-Synthase (Requires Vitamin B6/Pyridoxine as cofactor).
  • Pathway: Transsulfuration pathway (Methionine $\rightarrow$ Homocysteine $\rightarrow$ Cystathionine $\rightarrow$ Cysteine).
  • Biochemical Defect: Block in conversion of Homocysteine to Cystathionine.
  • Consequences:
    • Accumulation of Homocysteine and Methionine.
    • Deficiency of Cysteine (becomes essential).
    • Toxicity: Elevated Hcy causes endothelial injury (thrombosis), interferes with collagen/elastin cross-linking (fibrillin-1 inhibition), and acts as an NMDA receptor agonist (neurotoxicity).

2. Remethylation Defects

  • Enzymes: Methylene Tetrahydrofolate Reductase (MTHFR) or Methionine Synthase.
  • Biochemistry: Failure to convert Homocysteine back to Methionine.
  • Profile: High Homocysteine but Low Methionine.

Clinical Features (Classic CBS Deficiency)

Multisystem involvement affecting Eyes, Skeleton, CNS, and Vascular system. Patients usually appear normal at birth.

1. Ocular (Key Feature)

  • Ectopia Lentis (Lens Dislocation):
    • Occurs in >85% of untreated patients.
    • Direction: Typically Downwards and Inwards (Inferonasal).
    • Onset: Usually by 3–4 years; almost all by 10 years.
  • Other: Severe Myopia, glaucoma, retinal detachment.

2. Skeletal (Marfanoid Habitus)

  • Appearance: Tall stature, long limbs (dolichostenomelia), arachnodactyly (long fingers).
  • Deformities: Pectus carinatum or excavatum, genu valgum, high-arched palate.
  • Bone Density: Severe Osteoporosis (distinct from Marfan syndrome) leading to pathological fractures and vertebral collapse ("codfish vertebrae").

3. Vascular (Major Cause of Morbidity/Mortality)

  • Thromboembolism: Can affect any vessel (arterial or venous) at any age.
  • Manifestations: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke (CVA) in young children, Myocardial Infarction.
  • Trigger: Surgery, dehydration, or immobilization can precipitate fatal thrombosis.

4. Central Nervous System

  • Intellectual Disability: Common (IQ 30–75) but variable; B6-responsive patients often have normal IQ.
  • Psychiatric: Anxiety, depression, obsessive-compulsive behavior.
  • Seizures: Occur in ~20% of patients.

5. Cutaneous

  • Malar Flush: Flushing of cheeks (distinctive).
  • Thin, fair skin and fair hair (hypopigmentation).

Investigations

1. Screening

  • Cyanide-Nitroprusside Test: Urine turns deep red/magenta (detects sulfhydryl groups).
    • False Negatives: Low protein intake.
    • False Positives: Cystinuria.
  • Newborn Screening (NBS): Detects elevated Methionine.
    • Limitation: May miss B6-responsive forms or remethylation defects (where Methionine is low).

2. Confirmatory Tests

  • Plasma Amino Acids:
    • Classic: Elevated Methionine, Elevated Homocysteine, Low Cysteine.
    • Remethylation Defect: Low Methionine, Elevated Homocysteine.
  • Plasma Total Homocysteine (tHcy): Markedly elevated (>100 µmol/L; Normal <15).
  • Enzyme Assay: CBS activity in cultured fibroblasts or liver biopsy.
  • Genetics: CBS gene mutation analysis.

3. Pyridoxine (B6) Challenge Test

  • Purpose: To determine B6 responsiveness (prognostic factor).
  • Method: Give 100–500 mg Vitamin B6 daily.
  • Response: Significant drop in plasma Hcy and Methionine implies B6-Responsive Homocystinuria (milder phenotype).

Management

1. B6-Responsive Patients (~50%)

  • Vitamin B6 (Pyridoxine): High dose (200–500 mg/day).
  • Goal: Maintain plasma Hcy <50 µmol/L.
  • Supplementation: Folate and Vitamin B12 (optimize remethylation).

2. B6-Non-Responsive Patients

  • Dietary Restriction:
    • Low Methionine Diet: Restrict animal protein (meat, dairy, eggs).
    • Medical Formula: Methionine-free amino acid mixture containing Cysteine.
  • Betaine (Trimethylglycine):
    • Mechanism: Donates methyl group to Homocysteine to form Methionine (alternate remethylation pathway independent of folate).
    • Indication: First-line adjunct in non-responsive cases.
    • Risk: Can excessively raise Methionine levels (monitor for cerebral edema risk if Met >1000 µmol/L).

3. General Measures

  • Anticoagulation: Not routine prophylactically, but aggressive hydration is mandatory during surgery or illness.
  • Eye Care: Regular ophthalmology follow-up; surgery for dislocated lenses.
  • Bone Health: Calcium, Vitamin D, exercise to manage osteoporosis.

Prognosis

  • Untreated: Poor life expectancy due to vascular events (50% mortality by age 20-30).
  • Treated:
    • B6-Responsive: Excellent prognosis; normal IQ and lifespan if treated early.
    • Non-Responsive: Good outcome if diet/Betaine started in neonates. Late treatment prevents further thrombosis but does not reverse ID or lens dislocation.